Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol
Tóm tắt
Từ khóa
Tài liệu tham khảo
Veterans Administration Cooperative Study Group on Antihypertensive Agents (1967) Effect of treatment on morbidity in hypertension. Results in patients with diastolic pressure averaging 115 through 129 mm Hg. JAMA 202: 116?122
Veterans Adminstration Cooperative Study Group on Antihypertensive Agents (1970) Effect of treatment on morbidity in hypertension. II. Results in patients with diastolic pressure averaging 90 through 114 mm Hg. JAMA 213: 1143?1152
Hypertension Detection and Follow-up Program Cooperative Group (1979) Five-year findings of the hypertension detection and follow-up program. JAMA 242: 2562?2571
Multiple Risk Factor Intervention Trial Research Group (1982) Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 248: 1465?1477
Samuelsson O (1985) Hypertension in middle-aged men: Management, morbidity and prognostic factors during long-term hypertensive care. Acta Med Scand [Suppl] 702: 1?79
Isles GC, Walker LM, Beevers GD, et al. (1986) Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 4: 141?156
Bulpitt CJ, Beevers G, Butler A, et al. (1986) The survival of treated hypertensive patients and their causes of death: A report from the DHSS Hypertensive Care Computing Project (DHCCP). J Hypertens 4: 93?100
Helgeland A (1980) Treatment of mild hypertension: a five-year controlled drug trial. The Oslo Study. AJR 69: 725?732
Medical Research Council Working Party (1985) MRC trial of treatment of mild hypertension: principal results. Br Med J 291: 97?104
Stamler J, Stamler R, Liu K (1985) High blood pressure: role in coronary heart disease and implications for prevention and control. In: Connor W, Bristow (eds) Coronary heart disease. Lippincott, Philadelphia, p 85
Carlsson LA, Åberg H (1985) Serum triglycerides ? an independent risk factor for myocardial infarction but not for angina pectoris. N Engl J Med 312: 1127
Carlsson LA, Böttiger LE, Åfeldt PE (1979) Risk factors for myocardial infarction in the Stockholm prospective study ? A 14 year follow-up focusing on the role of plasma triglyceride and cholesterol. Acta Med Scand 206: 351
Hamsten A, Wiman B, De Faire U, Blombäck M (1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313: 1557?1563
Hamsten A, Walldius G, Blombäck M, de Faire U, Dahlén G, Landou C, Wiman B (1987) Plasminogen activator inhibitor in plasma: riskfactor for recurrent myocardial infarction. Lancet II: 3?8
Nilsson TK, Johnson O (1987) The extrinsic fibrinolytic system in survivors of myocardial infarction. Thromb Res 48: 621?630
Olofsson B-O, Dahlén G, Nilsson TK (1989) Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 10: 77?82
Nilsson TK, Lithner F (1988) Glycaemic control, smoking habits and diabetes duration affect the extrinsic fibrinolytic system in type I diabetic patients but microangiopathy does not. Acta Med Scand 224: 123?129
Sundell B, Nilsson TK, Nygren C, Hallmans G, Hellsten G, Dahlén GH (1989) Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in an North Swedish population. Atherosclerosis 80: 9?16
Simpson HCR, Meade TW, Stirling Y, Mann JI, Chakrabarti R, Woolf L (1983) Hypertriglyceridaemia and hypercoagulability. Lancet I: 786?790
Andersen P, Nilsen DWT, Beckman SL, Holme I, Hjermann I (1988) Increased fibrinolytic potential after diet intervention in healthy coronary high-risk individuals. Acta Med Scand 223: 499?506
Meade TW, Brozovic M, Chakrabarti R, et al. (1986) Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart study. Lancet I: 533?537
Jansson JH (1990) Studies on haemostatis in deep vein thrombosis, ischaemic heart disease and hypertension. Umeå University Medical Dissertations New Series No 295 Paper V
Huhtasaari F, Asplund K, Wester PO (1988) Cardiovascular risk factors in the northern Sweden MONICA study. Acta Med Scand 224: 99?108
Nyström L, Rosén M, Wall S (1986) Why are diabetes, stomach cancer and circulatory diseases more common in Northern Sweden? Scand J Prim Hlth Care 4: 5?12
Krarup NB (1956) Fetma. Vår Hälsa 9: 3?14
Grimaudo V, Hauert J, Bachman F, Kruithof EKO (1988) Diurnal variation of the fibrinolytic system. Thromb Haemostas 59: 495?499
Bergsdorf N, Nilsson T, Wallén P (1983) An enzyme-linked immunosorbent assay for tissue plaminogen activator applied to patients with thromboembolic disease. Thromb Haemostas 50: 740?744
Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G (1986) Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 32: 2160?2165
Wiman B, Mellbring G, Rånby M (1983) Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 127: 279?288
Chmielewska J, Rånby M, Wiman B (1983) Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 31: 427?436
Paramo JA, Colucci M, Collen D, van de Werf P (1985) Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 291: 573?574
Aznar J, Estellés A, Tormo G et al. (1988) Plasminogen activator inhibitor and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 59: 535?541
Francis RB, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI (1988) Impaired fibrinolysis in coronary artery disease. Am Heart J 115: 776?780
Mehrotra TN, Mehrotra R (1987) Platelet adhesiveness, plasma fibrinogen and fibrinolytic activity in cases of essential hypertension. J Postgraduate Med 33: 178?181
Reference deleted
Kartsev AN (1986) Fibrinolysis and platelet reactivity in patients with essential hypertension and coronary atherosclerosis. Klinicheskaia meditsina 64: 103?107 (in Russian)
Khamidov NK, Khamdamova MB (1987) Fibrinolytic blood system in ischemic heart disease concurrent with arterial hypertension in middle and old age. Klinicheskaia meditsina 65: 74?76 (in Russian)
Jansson JH (1990) Studies on haemostasis in deep vein thrombosis, ischaemic heart disease and hypertension. Umeå University Medical Dissertations New Series No. 295 Paper V
Elkeles RS, Chakrabarti R, Vickers M, Stirling Y, Meade TW (1980) Effect of treatment of hyperlipidemia on haemostatic variables. Br Med J 281: 973?974
Sacks FM, Dzau VJ (1986) Adrenergic effects on plasma lipoprotein metabolism. Am J Med 80 [Suppl 2A]: 71
Frick H, Cox D, Himanen P et al. (1987) Serum lipid changes in a one-year multicenter, double-blind comparison of doxazosin and Atenolol for mild to moderate essential hypertension. Am J Cardiol 59: 616?676
Trost B, Weidmann P, Riesen W, Claessens J, Streulens Y, Nelemans F (1987) Comparing effects of doxazosin and hydrochlortiazidd on serum lipids and blood pressure in essential hypertension. Am J Cardiol 59: 996?1046
Hjortdal P, von Krogh H, Daae L, Holme I, Hjerman I (1987) A 24-week multicenter double-blind study of doxazosin and hydrochlorthiazide in patients with mild to moderate essential hypertension. Acta Med Scand 221: 427?434
Holemans R (1963) Enchancing the fibrinolytic activity of the blood by vasoactive drugs. Med Exp 9: 5?12
Gader AMA, Clarkson AR, Cash JD (1973) The plasminogen activator and coagulation factor VIII response to adrenaline, noradrenaline, isoprenaline and salbutamol in man. Thromb Res 2: 9?16
Kral JG, Åblad B, Johnsson G, Korsan-Bengtsson K (1971) Effects of adrenaline and alprenolol on blood coagulation and fibrinolysis in man. Eur J Clin Pharmacol 3: 144?147
Probst A, Lill H, Strain KM (1988) Beta-adrenergic receptor mediated release of tissue plasminogen activator in anaesthetized dogs. Thromb Res 50: 9?17
Winther K (1987) The effect of beta-blockade on platelet function and fibrinolytic activity. J Cardiovasc Pharmacol 10 [Suppl 2]: S 94?98
Johannessen KA, Nordrehaug JE, von der Lippe G (1987) Increased occurrence of left ventricular thrombi during early treatment with timolol in patients with myocardial infarction. Circulation 75: 151?155
Alexander GGT, Robinson JG, Doyle DJ et al. (1989 Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 320: 352?357
Norwegian Study group (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801